|
13 Jan 2023 |
Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 Antibody by the U.S. FDA
|
|
12 Jan 2023 |
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
|
|
11 Jan 2023 |
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
|
|
11 Jan 2023 |
Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases
|
|
11 Jan 2023 |
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
|
|
11 Jan 2023 |
Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia
|
|
10 Jan 2023 |
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
|
|
09 Jan 2023 |
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
|
|
09 Jan 2023 |
Alloy Therapeutics Unveils 2023 Innovation Roadmap Across Antibodies, TCRs, Bispecifics, and Genetic Medicines
|
|
09 Jan 2023 |
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
|
|
09 Jan 2023 |
Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1
|
|
07 Jan 2023 |
HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
|
|
07 Jan 2023 |
Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
|
|
07 Jan 2023 |
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
|
|
07 Jan 2023 |
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
|
|
06 Jan 2023 |
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
|
|
06 Jan 2023 |
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
|
|
06 Jan 2023 |
FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma
|
|
05 Jan 2023 |
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
|
|
05 Jan 2023 |
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs
|
|
05 Jan 2023 |
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
|
|
05 Jan 2023 |
IntoCell Enters into Development and License Option Agreement with ADC Therapeutics
|
|
05 Jan 2023 |
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
|
|
05 Jan 2023 |
Nirsevimab US regulatory submission accepted for the prevention of RSV lower respiratory tract disease in infants and children up to age 24 months
|
|
04 Jan 2023 |
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
|
